Antidiabetes drugs semaglutide and tirzepatide potentially lower dementia and stroke risk by up to 37% in patients with type 2 diabetes and obesity.
“However, newer antidiabetes drugs may mitigate this risk. A recent study found that people taking the antidiabetes drugs semaglutide or tirzepatide were 37% less likely to develop dementia than those taking other diabetes medications.”